Spectral AI Comments on Compliance with Nasdaq Listing Rule 5550(b)(2)
Spectral AI (NASDAQ: MDAI) announced it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2) by maintaining a market value of listed securities above $35 million for 10 consecutive business days. The company, which develops the DeepView® System (an AI-driven technology with FDA Breakthrough Device Designation for burn healing prediction), has notified Nasdaq and awaits official confirmation of compliance.
Spectral AI (NASDAQ: MDAI) ha annunciato di ritenere di aver riacquistato la conformità con la Regola di Quotazione del Nasdaq 5550(b)(2) mantenendo un valore di mercato dei titoli quotati superiore a 35 milioni di dollari per 10 giorni lavorativi consecutivi. L'azienda, che sviluppa il DeepView® System (una tecnologia basata su IA con Designazione di Dispositivo Innovativo da parte della FDA per la previsione della guarigione delle ustioni), ha informato il Nasdaq e attende conferma ufficiale della conformità.
Spectral AI (NASDAQ: MDAI) anunció que cree haber recuperado la conformidad con la Regla de Cotización del Nasdaq 5550(b)(2) al mantener un valor de mercado de los valores cotizados por encima de 35 millones de dólares durante 10 días hábiles consecutivos. La compañía, que desarrolla el DeepView® System (una tecnología impulsada por IA con Designación de Dispositivo Innovador de la FDA para la predicción de la cicatrización de quemaduras), ha notificado al Nasdaq y espera la confirmación oficial de la conformidad.
스펙트럴 AI (NASDAQ: MDAI)는 상장 규칙 5550(b)(2) 준수를 회복했다고 믿고 있으며, 최근 10영업일 연속으로 상장 증권의 시장 가치가 3,500만 달러를 초과했다고 발표했습니다. 이 회사는 DeepView® System (화상 치유 예측을 위한 FDA 혁신형 기기 지정의 AI 기반 기술)을 개발하고 있으며, 나스닥에 통지하였고 준수 여부에 대한 공식 확인을 기다리고 있습니다.
Spectral AI (NASDAQ: MDAI) a annoncé croire qu'elle a retrouvé la conformité avec la Règle de Cotation du Nasdaq 5550(b)(2) en maintenant une valeur de marché des titres cotés supérieure à 35 millions de dollars pendant 10 jours ouvrables consécutifs. L'entreprise, qui développe le DeepView® System (une technologie basée sur l'IA avec désignation de dispositif novateur de la FDA pour la prédiction de la guérison des brûlures), a informé le Nasdaq et attend la confirmation officielle de conformité.
Spectral AI (NASDAQ: MDAI) gab bekannt, dass sie glaubt, die Konformität mit der Nasdaq-Börsenregel 5550(b)(2) wiederhergestellt zu haben, indem sie den Marktwert der gelisteten Wertpapiere über 35 Millionen US-Dollar für 10 aufeinanderfolgende Geschäftstage gehalten hat. Das Unternehmen, das das DeepView® System (eine KI-gesteuerte Technologie mit der FDA-Ansicht für innovative Geräte zur Vorhersage der Heilung von Verbrennungen) entwickelt, hat Nasdaq benachrichtigt und wartet auf die offizielle Bestätigung der Konformität.
- Market value exceeded $35 million for 10 consecutive business days
- Expected regaining of Nasdaq listing compliance
- Previous FDA Breakthrough Device Designation status maintained
- Awaiting final confirmation from Nasdaq for compliance status
- Recent history of falling below minimum market value requirement
Insights
The market cap compliance announcement is a positive development for Spectral AI's listing status, alleviating immediate delisting concerns. With a current market cap of
DALLAS, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced today that the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities of
The market value of Spectral AI’s common stock has exceeded
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to separate its Spectral IP subsidiary from the Company, and each Company’s strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.
For Media and Investor Relations, please contact:
David Kugelman
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Email: dk@atlcp.com
FAQ
What is the minimum market value requirement for Spectral AI (MDAI) to maintain Nasdaq listing?
How long did Spectral AI (MDAI) need to maintain $35M market value to regain compliance?
When did Spectral AI's DeepView System receive FDA Breakthrough Device Designation?
What is the current status of Spectral AI's (MDAI) Nasdaq compliance in December 2024?
